Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cara Therapeutics Inc shares valued at $1,064 were sold by Posner Christopher on Nov 04 ’24. At $0.29 per share, Posner Christopher sold 3,668 shares. The insider’s holdings dropped to 168,768 shares worth approximately $43879.68 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Posner Christopher sold 4,149 shares, netting a total of over 1,452 in proceeds. Following the sale of shares at $0.35 each, the insider now holds 172,436 shares.
Before that, Posner Christopher had sold 3,936 shares from its account. In a trade valued at $2,952, the PRESIDENT AND CEO traded Cara Therapeutics Inc shares for $0.75 each. Upon closing the transaction, the insider’s holdings decreased to 3,936 shares, worth approximately $45912.1.
As published in a research note from Stifel on June 13, 2024, Cara Therapeutics Inc [CARA] has been rated down from a Buy to a Hold and the price target has been revised to $1 from $6. Analysts at Needham downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid June. As of June 13, 2024, H.C. Wainwright has decreased its “Buy” rating to a “Neutral” for CARA. Earlier on June 13, 2024, Canaccord Genuity downgraded its rating. Their new recommendation was “a Hold” for CARA stock which previously was a “a Buy”.
Analyzing CARA Stock Performance
During the last five days, there has been a drop of approximately -1.84%. Over the course of the year, Cara Therapeutics Inc shares have dropped approximately -64.72%. Shares of the company reached a 52-week high of $1.1500 on 03/04/24 and a 52-week low of $0.2257 on 12/18/24. A 50-day SMA is recorded $0.2852, while a 200-day SMA reached $0.4684. Nevertheless, trading volume fell to 22.95 million shares from 1.38 million shares the previous day.
Support And Resistance Levels for Cara Therapeutics Inc (CARA)
According to the 24-hour chart, there is a support level at 0.2346, which, if violated, would cause prices to drop to 0.2072. In the upper region, resistance lies at 0.2806. The next price resistance is at 0.2992. RSI (Relative Strength Index) is 42.27 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.0153, which suggests the price will decrease in the coming days. Percent R is at 56.82%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
